Gene Therapy Firm AMT Forced To Go Private, Backed By Forbion
This article was originally published in The Pink Sheet Daily
Executive Summary
Amsterdam Molecular Therapeutics plans to be acquired by a newly formed private company, uniQure, and to delist from Euronext.